Kornimate/medical-research-clean huggingface dataset:
effect of adalimumab therapy on psoriasis patient

Conditions: Psoriasi

Summary: to evaluate the impact of adalimumab therapy on quality of life in patient with severe psoriasis.

to evaluate the impact of adalimumab therapy against methotrexate therapy on quality of life in patient with severe psoriasis and follow up after 24 week by a- medical history age, sex, marital state, occupation, educational level and family history. dermatologic history: onset, course, duration. b- complete dermatologic examination c- psoriasis area and severity index (pasi) score: the scoring involves rating the symptoms of psoriasis from none to very severe and estimating the percentage of the body that they affect.the range of absolute pasi scores is 0-72, with higher scores indicating a greater severity of psoriasis. a score of 0 indicates no psoriasis, while a score higher than 10 suggests severe psoriasis. the scoring system includes a section for intensity and another for body coverage .the score will be evaluated before treatment, at week 12 and at week 24. d- dermatology life quality index (dlqi): it is self-reported questionnaire . it has been translated to \>110 languages. measurement properties of the dlqi, such as validity, reliability, and responsiveness to change were reported. it is widely used in both clinical practice and research settings, including randomized controlled trials, patient registries, and national treatment and reimbursement guidelines . the study will depend on the arabic tunisian version of the dlqi questionnaire . dlqi consists of 10 questions related to symptoms, feelings, daily activities, leisure, work, personal relationships and the effects of treatment on daily life within the past week. scores can range from 0 to 30, with higher scores representing worse quality of life . the questionnaire will be answered by all participant before initiation of treatment, at week 12 and at week 24 of treatment.

Eligibility criteria:
inclusion criteria: .adult patients (\> 18 years) with severe psoriasis who will start treatment with either adalimumab or methotrexate. exclusion criteria: .pregnancy or lactation. .chronic liver or renal disease. .history of tuberculosis. .cancer and blood disorder.
acupuncture for chronic prostatitis/chronic pelvic pain syndrome

Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome

Summary: chronic prostatitis/chronic pelvic pain syndrome (cp/cpps) refers to the presence of bothersome pelvic pain symptoms without an identifiable cause. common symptoms of cp/cpps include discomfort in the perineum, suprapubic region, and lower urinary tract symptoms. it affects men of all ages without apparent racial predisposition, among which, 36-50 years old are the most commonly influenced. yet, few effective therapies are available for treating cp/cpps. acupuncture may be an effective treatment option for cp/cpps. however, effects of acupuncture on cp/cpps remain uncertain because of the small sample sizes or other methodological limitations. the objective of this multi-centre, randomized, sham acupuncture-controlled trial is to assess the effectiveness of acupuncture for relieving symptoms of cp/cpps. the results will provide a robust conclusion with a high level of evidence.


Eligibility criteria:
inclusion criteria: * 1.history of pain perceived in the prostate region and absence of other lower urinary tract pathology for a minimum of three of the past 6 months. in addition, any associated lower urinary tract symptoms, sexual function, and psychological factors should be addressed. physical examinations, urinary analyses, and urine cultures will be performed for all subjects; * 2. age 18 to 50 years. * 3. nih chronic prostatitis symptom index (nih- cpsi) total score ≥ 15. exclusion criteria: * 1. prostate, bladder, or urethral cancer, seizure disorder in any medical history. * 2. inflammatory bowel disease, active urethral stricture, neurologic disease or disorder affecting the bladder, liver disease, neurologic impairment or psychiatric disorder preventing understanding of consent and self-report scale. * 3. urinary tract infection with a urine culture value of more than 100,000 cfu/ml, clinical evidence of urethritis, including urethral discharge or positive culture, diagnostic of sexually transmitted diseases (including gonorrhoea, chlamydia, mycoplasma or trichomonas, but not including hiv/aids), symptoms of acute or chronic epididymitis). * 4. residual urine volume≥100ml. * 5. qmax≤15ml/s. * 6. prior 4 weeks used androgen hormone inhibitors (finasteride), alpha-blockers (terazosin hci, doxazosin mesylate, tamsulosin hydrochloride), antibiotics (ciprofloxacin hydrochloride), or any other prostatitis-specific medication (including herb and chinese medicine).

Keywords: chronic prostatitis chronic pelvic pain syndrome acupuncture randomized controlled trial
immune response to third dose of sars-cov-2 vaccine in a cohort of cancer patients on active treatment

Conditions: Sars-CoV-2 Infection

Summary: the coronavirus disease 2019 (covid-19) pandemic has claimed over 5 million lives globally. fortunately, a substantial and growing number of sars-cov-2 vaccines with very high efficacy have been developed, manufactured, and rapidly approved. novel mrna vaccines such as the bnt162b2 (pfizer-biontech) and mrna-1273 (moderna) have reported a stunning \>94% efficacy against covid-19. however, global access has not been equitable, with many low- and middle-income countries having no vaccine access or access under emergency use mainly to traditional inactivated sars-cov2-2 vaccines such as bbibp-corv (sinopharm beijing), coronavac (sinovac) and bbv152 (bharat biotech). emerging studies have shown that lower concentrations of neutralizing antibodies (nab) are attained after coronavac than after a mrna-based vaccine in healthy individuals. this difference seems to be more pronounced in immunocompromised patients who are at higher risk of severe covid-19 and death from covid-19. as such several countries including united states, israel and chile have recommended a third vaccine dose for this vulnerable population. in this observational study we will explore the humoral response to the bnt162b2 vaccine in patients who received two previous doses of the inactivated vaccine coronavac or two doses of bnt162b2.


Eligibility criteria:
inclusion criteria: * vaccination with two doses of coronavac vaccine or bnt162b2 vaccine * eastern cooperative oncology group performance status \< 3 exclusion criteria: * previous sars-cov-2 infection * vaccination with booster vaccine more than 12 weeks before informed consent * intravenous inmunoglobulin therapy 60 days before informed consent * any condition that could interfere with the paticipant´s participation during the study in the opinion of the treating investigator.
aripiprazole in late life bipolar disorder

Conditions: Bipolar Disorder

Summary: the purpose of this research study is to analyze the effectiveness and tolerability of a new medication, aripiprazole (abilify), in individuals age 50 years and older who have bipolar disorder (manic-depressive illness).

while medications such as valproate (depakote and others) and lithium are generally considered first-line agents in late life bipolar disorder, side effects are common, and many individuals with bipolar disorder continue to have symptoms in spite of medication treatment. a continuing unmet need is the availability of medications that are generally well- tolerated and effective in later life bipolar disorders. antipsychotic medications such as abilify are known to be effective for related conditions such as schizophrenia and are also used by some physicians in clinical settings in combination with mood stabilizing medications (lithium, depakote and others) to treat symptoms of bipolar disorder. currently abilify is approved by the fda to treat schizophrenia and to treat bipolar disorder.

Eligibility criteria:
inclusion criteria: * must have bipolar disorder as confirmed by the mini neuropsychiatric interview (mini) * must be age 50 or older * must have sub-optimal response to current psychotropic management including at least one of the following: * behaviors and symptoms of irritability, agitation, mood liability or diminished ability to interact with others in their place of residence * diminished ability to take care of basic personal needs in their place of residence due to symptoms of bipolar disorder * intolerance to current psychotropic medications; and * must live in the northeast ohio area. exclusion criteria: * an unstable medical illness, or a medical illness, which in the opinion of the study investigators, is likely to affect the outcome of the study * dsm-iv substance dependence (except nicotine or caffeine) within the past 3 months; or * receiving carbamazepine.

Keywords: bipolar disorder geriatric psychiatry aripiprazole
comparative study of specular microscopes for measurements of cell density, coefficient of variation and hexagonality

Conditions: Corneal Endothelial Cell Loss

Summary: the primary objective of this clinical study is to collect clinical data to support an fda 510(k) submission for the nidek cem-530 center point method and corner point method. the secondary objective is to evaluate any adverse events found during the clinical study.

the primary objective of this clinical study is to collect clinical data to support an fda 510(k) submission for the nidek cem-530 center point method and corner point method.

Eligibility criteria:
inclusion criteria: * non-pathologic: male or female subjects from 18 to 80 years old who have full legal capacity to volunteer on the date the informed consent is signed. subjects who can follow the instructions by the clinical staff at the clinical site,and can attend examinations on the scheduled examination date. subjects who agree to participate in the study. * pathologic: male and female subjects from 29 to 80 years old who have full legal capacity to volunteer on the date the informed consent is signed. subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date. subjects who agree to participate in the study. at least one eye with any of the following conditions: * history of post-op surgical trauma including bullous keratopathy * history of corneal transplant * physical injury or trauma to the cornea * long term fuch's dystrophy, guttata or other corneal endothelial dystrophies * keratoconus * long term pmma contact lens use (greater than 3 years) exclusion criteria: * non-pathologic: male and female subjects from 29 to 80 years old who have full legal capacity to volunteer on the date the informed consent is signed. subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date. subjects who agree to participate in the study. at least one eye with any of the following conditions: * history of post-op surgical trauma including bullous keratopathy * history of corneal transplant * physical injury or trauma to the cornea * long term fuch's dystrophy, guttata or other corneal endothelial dystrophies * keratoconus * long term pmma contact lens use (greater than 3 years) * pathologic: history of cataract, refractive or ocular surgical procedures that render the cornea opaque or otherwise impact its ability to be imaged using the investigational device. fixation problems which may prevent obtaining at least poor quality (refer to figure 1) cem-530 and konan cellchek plus images in either eye.
differential expression and potential value of c-myc in non-invasive and invasive mammary carcinoma

Conditions: Invasive Breast Cancer

Summary: retrospective observational study to evaluate c-myc expression in non invasive and invasive mammry carcinoma

to correlate different levels of c-myc expressions with variable clinical and pathological parameters of mammary carcinoma (such as patients' ages, tumor grading, staging, laterality, focality and nodal metastasis, co-existing in-situ components). this study will be carried out on archived formalin-fixed and paraffin embedded tissue blocks that were belonged to 70 women with breast lumps.

Eligibility criteria:
inclusion criteria: specimens of modified radical mastectomies from breast carcinoma patients exclusion criteria: * cases with insufficient clinical data. * tissue blocks of destroyed or insufficient material, unfit for diagnosis. * cases who received pre-operative chemotherapy.
sympathetic nervous system mediation of acute exercise effects on childhood brain and cognition

Conditions: Exercise; Cognition

Summary: today's children have become increasingly inactive and unfit, with \>50% of children not meeting the recommended 60 min of moderate-to-vigorous physical activity. previous research has suggested that acute aerobic exercise of moderate intensity was associated with improved cognition manifested by improved performance and increased p3 amplitude, a neuroelectric indicator that reflects the amount of attentional allocation, in tasks requiring cognitive control. while minimal evidence exists to support potential mechanisms underlying the transient effects of exercise on brain and cognition, research suggests that phasic changes in the locus coeruleus-norepinephrine (lc-ne) (as measured by salivary alpha amylase (saa)) system are a potential mechanism for explaining the acute effect of exercise on brain and cognition. accordingly, the aim of this study is to examine the mechanisms linking acute aerobic exercise to improved cognitive control as well as the underlying neuroelectrical activities in children, using electroencephalography (eeg) and event-related potentials (erps). we hope to gain a better understanding of the role of acute exercise and cognitive and brain health. the results from this study will help identify mechanisms linking acute exercise to enhanced cognitive performance in children. our hypothesis is that exercise-induced phasic increases in sympathetic nervous system activity will mediate the effect of a single bout of exercise on brain function, cognition, and standardized achievement test performance.


Eligibility criteria:
inclusion criteria: * parental/guardian consent (non-consent of guardian). * participants must have had no prior diagnosis of cognitive or physical disability, including attention deficit hyperactivity disorder (severe asthma, epilepsy, chronic kidney disease, and dependence upon a wheelchair/walking aid). * participants must be free of any type of anti-psychotic, anti-depressant, anti-anxiety medication, as well as those medications used for attention deficit hyperactivity disorder (use of any anti-psychotic, anti-depressant, anti-anxiety, and attention deficit hyperactivity disorder medications). * normal or corrected-to-normal vision based on the minimal 20/20 standard in order to complete the cognitive task (below 20/20 vision). * participants must have not yet reached, or be in the earliest stages, of puberty, as measured by a modified test of the tanner staging system (onset of puberty as determined by tanner). * english speaking. exclusion criteria: * participants with an intelligence quotient below 85 will be excluded.
computational mathematical analysis in vastus medialis between a mtrp and non painful point

Conditions: Trigger Point Pain, Myofascial

Summary: with the help of ultrasound, the goal of the study is to asses the differences between mtr points and non painful points, in order to characterize the identification of mtr througought ultrasound. being a complex process that needs to be standarized for each muscle, the study takes place in the vastus medialis.

nowadays, myofascial trigger points (mtrp) represent one of the most common musculoskeletal alterations in clinic, being many times diffuse and complex to diagnose and localize. ultrasound is a therapeutic tool used in physiotherapy for assessment and treatment. some of its advantages include the quickness and harmlessness. linking these two concepts, there is no vast evidence regarding the identification of myofascial trigger points through ultrasound. a computational mathematical analysis was performed throughout ultrasound images of the vastus medialis in order to characterize mtrps, where images of 66 participants vastus medialis were taken. two investigators made the finger point palpation locating a mtrp and a non-painful point. a third investigator screened the photographs with the ultrasound and a preset for the zone. 3 images were taken from the mtrp, 3 from the non-painful point, and other 3 of a different mtrp, in case the investigators disagreement of the mtrp location. a fourth investigator carried out the histogram analysis using fiji software. lastly, stastistical analysis of the study variables was performed.

Eligibility criteria:
inclusion criteria: * 18-65 year old. * presence of pain on palpation along the course of the muscle fibers of the vastus medialis of the quadriceps. * painful point and/or localized tense band with or without radiation of pain to the knee area or adductor region. exclusion criteria: * serious diseases (neurological, psychiatric, systemic diseases, obesity). * knee or hip surgeries. * muscle tears in a state of recovery in the vastus medialis of the quadriceps. * inability to position yourself in a lateral decubitus position.

Keywords: ultrasound myofascial trigger point vastus medialis
beneficial effects of magnesium supplementation on idiopathic muscle cramps

Conditions: Muscle Cramp

Summary: the goal of this study is to evaluate the effectiveness of magnesium supplements (magtabsr 168 mgs twice daily) for relief and/or improvement in the frequency, duration, and intensity of chronic leg cramps. improvement in sleep disturbances and quality of life will also be evaluated.

chronic leg cramps are prevalent among the aging population affecting sleep patterns and quality of life. magnesium deficiency may cause muscle weakness and cramps. magnesium supplementation will be evaluated for the relief and/or improvement of symptoms. the primary objective is to evaluate the efficacy of magnesium supplementation, magtabsr, 168mg's twice a day, for the relief and/or improvement in the frequency, duration, intensity of leg cramps. secondary objectives are to evaluate the improvement in sleep disturbances and quality of life.

Eligibility criteria:
inclusion criteria: * 40-85 years old * no kidney impairment * 2 or more leg cramps per week for last 30 days exclusion criteria: * \ 85 years old * kidney impairment * \< 2 leg cramps per week for last 30 days * enrolled in another research study * history of seizure disorder * current treatment with lithium * malabsorption or major intestinal disorders * significantly elevated magnesium level * history of allergy to magnesium compound * use of quinine for leg cramps * history of significant diarrhea * history of drug or alcohol abuse in the last 2 years * currently diagnosed with a terminal illness
a pk study to compare gme751 (proposed pembrolizumab biosimilar) and us-licensed and eu-authorized keytruda® in participants with stage ii and iii melanoma

Conditions: Melanoma

Summary: the purpose of this study is to investigate the pharmacokinetic (pk) similarity and efficacy, safety, and immunogenicity of gme751 compared with keytruda® (pembrolizumab) in subjects with resected advanced melanoma requiring adjuvant treatment with pembrolizumab.

eligible subjects will be randomized in a 1:1:1 ratio to receive either gme751, food and drug administration (fda)-licensed pembrolizumab (keytruda-us) or european union (eu)-authorized pembrolizumab (keytruda-eu). the maximum study duration for a participant will be approximately 28 weeks including screening. treatment duration is 24 weeks (4 treatment cycles, each of 6 weeks duration). however, subject should discontinue study participation in case of disease recurrence, unacceptable toxicity or other reasons. participants who are benefiting from treatment with pembrolizumab without signs of recurrence or unacceptable toxicity will be eligible for continued pembrolizumab treatment via most suitable option based on the respective country regulations.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * advanced melanoma * completely removed melanoma by surgery performed within 13 weeks of randomization * adequate organ function * subject has an eastern cooperative oncology group (ecog) performance status score of 0 or 1 exclusion criteria: * known history or evidence of ocular or uveal melanoma * known history of hypersensitivity (grade ≥3) to pembrolizumab or its excipients * known history of auto-immune disease * received live vaccine ≤30 days before the first study treatment * prior treatment with anti-pd-1 agents or agent against another stimulatory or co-inhibitory t cell receptor * active autoimmune disease that has necessitated chronic systemic treatment within 2 years before the first study treatment other protocol-defined inclusion/exclusion criteria apply
cerebrovascular hemodynamics in patients with ards.

Conditions: ARDS

Summary: the acute respiratory distress syndrome (ards) is a life-threatening disease with functional impairment of the lung. it is characterized by an excessive inflammatory response of lung tissue, capillaries, and blood vessels and is associated with high mortality. patients who survive the acute phase of this critical disease often suffer from long-term physical, psychological, and mental sequelae, as well as persistent cognitive deficits. in healthy individuals, autoregulatory mechanisms of the intracranial blood vessels keep blood supply to the brain independent of fluctuations in systemic blood pressure. in the case of a serious illness, these mechanisms of autoregulation may be impaired, which may favor cerebral hypoperfusion. impairment of cerebrovascular hemodynamics can lead to neuronal damage in short and long term. the aim of this project is to investigate cerebrovascular autoregulation in adult patients with ards and to evaluate the cognitive outcome at 3, 6 and 12 months after discharge from the intensive care unit.


Eligibility criteria:
inclusion criteria: * ards exclusion criteria: * pre-existing neurological diseases with known intracranial pathology * cerebrovascular disorders, including hemodynamically relevant extracranial vascular stenoses

Keywords: cerebral autoregulation cerebral hemodynamics cognitive impairment near-infrared spectroscopy